Robert J. Alpern - 31 Mar 2026 Form 4 Insider Report for AbbVie Inc. (ABBV)

Reporting relationship: Director
Issuer ticker: ABBV
Reported as of: 31 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Apr 2026, 17:00:11 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ T.O. Odutayo, Attorney-in-Fact for Robert J. Alpern

Key filing fact

Robert J. Alpern filed Form 4 for AbbVie Inc. (ABBV) on 02 Apr 2026.

Key facts

This page summarizes Robert J. Alpern's Form 4 filing for AbbVie Inc. (ABBV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Apr 2026, 17:00.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001448074 Primary reporting owner

Alpern Robert J

Relationship: Director
Address: 1 N. WAUKEGAN ROAD, NORTH CHICAGO
Signature: /s/ T.O. Odutayo, Attorney-in-Fact for Robert J. Alpern
Signature date: 02 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABBV transaction Derivative

Stock Equivalent Units

Award

Transaction value
Shares: +35
Change %: +0.34%
Price: $217.49^*
Shares after: 10,369
Date: 31 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35
Exercise price: $217.49
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

Footnote F2

Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.